Scientific Advisors

Prisyna science advisors include internationally respected leaders in oral health.

Hal Oien, DMD, MAGD President Jordco, Inc. and GSEM

Dr. Oien is the President of Jordco, Inc. and President of GSEM, two companies that produce innovative solutions in oral health products. He has operated a private practice in general dentistry and currently conducts biomedical and biomaterials research. His active research focuses on product development of oral therapies, and he has published regularly on oral topical rinses for analgesics, management of mucositis, and hemostasis of oral surgery wounds. He has extensive experience with bringing products through the Dental and Cardiovascular Surgery Branches of the Office of Combination Products at the FDA and oversight of FDA audits, multiple (7) Premarket Notification 510(k), FDA PMA and validation for ISO 13483 approval. Dr. Oien also holds several US Patents.

Edmond Truelove, DMD University of Washington

Dr. Truelove is recently retired Chair of the Department of Oral Medicine, University of Washington School of Dentistry, currently Head of Clinical Research. He was recently elected to a three-year term in the 2009 Washington State Dental Association’s House of Delegates. Dr. Truelove’s interests focus on oral medicine patient care including the management of patients with diseases of the oral soft tissues, oral cancer care, and oral cancer therapy complications, facial pains and Temporomandibular Disorders, atypical conditions such as sensory and motor dysfunctions of the jaws, salivary disorders, behavioral medicine as relates to oral symptoms and conditions, and orofacial diagnostic imaging. He has run numerous clinical trials in support of oral health products.

Joel Epstein, DMD, MSD, FRCD(C), FRCD(BC) Cedar-Sinai (UCLA), City of Hope Hospitals

Dr. Epstein is Professor and Department head, Oral Medicine and Diagnostic Sciences at the University of Illinois at Chicago. He is an expert on oral oncology and oral cancer diagnostics and has strong interest in treatments that can help the survivability of immunocompromised patients. He is a Diplomat of the American Board of Oral Medicine and has served as an examiner of the Board and as President. He was previously on the medical/dental staff of the British Columbia Cancer Agency; and Vancouver Hospital and Health Sciences Centre. He has published extensively in the area of oncology, infectious disease, facial pain and general areas of Oral Medicine.